CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Xechem International, Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Xechem International, Inc
Suite A3, 1550 Main Street
Phone: (970) 377-9554p:970 377-9554 WINDSOR, CO  80550  United States Ticker: XKEMXKEM

On 12/17/2014, the Company's bankruptcy case (#08-30513) was closed in the U.S. Bankruptcy Court for the Northern District of Illinois (Chicago).
This company is no longer actively traded on any major stock exchange.

Business Summary
Xechem International, Inc. is a holding company that owns all of the capital stock of Xechem, Inc., a development stage biopharmaceutical company engaged in the research and technology development of generic and drugs from natural sources. Research and development efforts focus principally on antifungal, anticancer, antiviral (including anti-AIDS) and anti-inflammatory compounds, as well as anti-aging and memory enhancing compounds. Xechem is also focusing on phytopharmaceuticals and other technologies for orphan diseases. As of December 31, 2006, the Company's lead project involved the development of a phytopharmaceutical product, NICOSAN/HEMOXIN). The development and production of NICOSAN/HEMOXIN is being conducted through Xechem Nigeria, Xechem Research Laboratories of Xechem, Inc. and Children’s Hospital of Philadelphia. In November 2008, the Company, along with Xechem, filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/200712/31/2006YesYesYes--

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Interim President, Chief Oversight Officer RobertSwift 8/16/2007 5/18/2007
Assistant Secretary, Director Stephen F.Burg 69 1/1/1996
Director Ramesh C.Pandey 68 7/5/2007 2/1/1994

Business Names
Business Name
Xechem (India) Pvt., Ltd.
Xechem International, Inc
Xechem Laboratories, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 80 (As of 12/31/2006)
Outstanding Shares: 1,641,396,853 (As of 5/10/2007)
Shareholders: 7,000
Stock Exchange: OTC
Federal Tax Id: 223284803
Fax Number: (302) 674-5266
Email Address: info@xechem.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023